Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari

pehlivan, sacide; NURSAL, Ayşe F; PEHLİVAN, MUSTAFA; SAHIN, Handan H.; TOMATIR, Ayse G

Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari

Mustafa PEHLİVAN, (Gaziantep University Faculty of Medicine, Department of Haematology, Gaziantep)

Ayse G TOMATIR, (Pamukkale University Faculty of Medicine, Department of Medical Biology, Denizli)

Ayşe F NURSAL, (Hitit University Faculty of Medicine, Department of Medical Genetics, Corum)

Handan H. SAHIN, (Gaziantep University Faculty of Medicine, Department of Haematology, Gaziantep)

SACİDE PEHLİVAN (Istanbul University Faculty of Medicine, Department of Medical Biology, Istanbul, TURKEY)

Uluslararası Hematoloji-Onkoloji Dergisi

7 0

Yıl: 2017 Cilt: 27 Sayı: 2 Sayfa Aralığı: 85 - 90 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari

Öz:

Nitrik oksit (NO) karsinogenezde karışık role sahiptir. Endotelial nitrik oksit sentaz (eNOS) geni üretilen NO'un çoğundan sorumludur. Bu nedenle, eNOS gen varyantlarının kansere yatkınlık ile ilişkili olduğu varsayılmaktadır. Bu çalışmanın amacı kronik lenfositik lösemili (KLL) Türk hastalarında eNOS (G894T ve intron 4 VNTR a/b) varyantlarının risk faktörü olup olmadığı saptamaktır. Bu çalışma, KLL hastalarında prospektif, tek merkezli kesitsel bir çalışmadır. Bu çalışmanın amacı eNOS varyantlarının (C894T ve 4VNTR b/a) Türk hastalarda Kronik lenfositik lösemi (KLL) riskini etkileyip etkilemediğini saptamaktır. Bu çalışmaya 60 KLL hastası ve benzer yaş ve cinsiyette 100 sağlıklı kontrol dahil edilmiştir. İki eNOS gen varyantı (G894T ve intron 4VNTR a/b) polimeraz zincir reaksiyonu (PZR) ve/veya restriksiyon fragman uzunluk polimorfizmi (RFLP) yöntemleri ile analiz edildi. Bu çalışmada, eNOS G894T varyantı TT genotipinin KLL hastalarında kontrole göre belirgin şekilde artmış risk ile ilişkili olduğunu bulduk (OR: 0.867, Cl: 0.785-0.957, p= 0.001). eNOS G894T allel dağılımında gruplar arasında belirgin fark yoktu (p> 0.05). Ayrıca eNOS intron 4'deki VNTR a/b varyant genotip ve allel sıklığı açısından KLL hastaları ve kontroller arasında belirgin fark saptanmadı. Bu çalışmada KLL hastalarındaki eNOS gen varyantları (G894T ve intron 4VNTR a/b) ilk defa eş zamanlı olarak incelenmiştir. Sonuçlarımız eNOS G894T varyantının Türk toplumunda KLL gelişmesi ile ilişkili olabileceğini önermektedir

Anahtar Kelime:

Konular: Hematoloji

The Endothelial Nitric Oxide Synthase Gene Variants as a Risk Factor for Chronic Lymphocytic Leukemia

Öz:

Nitric oxide (NO) plays complicated roles in carcinogenesis. Endothelial nitric oxide synthase (eNOS) gene is responsible for most of the NO produced. For this reason, it was considered that the eNOS gene variants is associated with cancer suspectibility. The aim of this study was to determine whether eNOS variants (G894T and intron 4 VNTR a/b) affect in Chronic Lymphocytic Leukemia (CLL) risk in Turkish patients. This is a prospective single-center crosssectional study in patients with CLL. A total of 60 CLL patients and 100 healthy controls with similar age and sex were included to this study. Two eNOS gene variants (G894T and intron 4VNTR a/b) were analysed with polymerase chain reaction (PCR) and/or restriction fragment length polymorphism (RFLP) methods. In this study, we found that the TT genotype of eNOS G894T variant was significantly associated with an increased risk in patient with CLL compared with control (OR: 0.867, Cl: 0.785-0.957, p= 0.001). There was not any significant difference in the eNOS G894T allele distribution between the groups (p> 0.05). In addition, no significant difference was detected between the CLL patients and healthy controls with respect to the frequencies of genotypes and alleles in intron 4 VNTR a/b variant of eNOS. eNOS gene variants (G894T and intron 4 VNTR a/b) in CLL patients were simultaneously analyzed for the first time in present study. Our study suggest that the eNOS G894T variant may be associated with the development of CLL in the Turkish population

Anahtar Kelime:

Konular: Hematoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hus I, Rolinski J. Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. Contemp Oncol (Pozn) 19: 361-367, 2015.
2. Landau DA, Wu CJ. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med 5: 47, 2013.
3. Vural F, Karaca E, Soyer N, et al. Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. UHOD 3: 179-184, 2014.
4 Haque S, Mandal RK, Akhter N, et al. G894T and 4a/b polymorphisms of NOS3 gene are not associated with cancer risk: a meta-analysis. Asian Pac J Cancer Prev 16: 2929-2937, 2015.
5. Yanar K, Çakatay U, Aydin S, et al. Relation between Endothelial Nitric Oxide Synthase Genotypes and Oxidative Stress Markers in Larynx Cancer. Oxid Med Cell Longev 2016: 4985063, 2016.
6 Albrecht EW, Stegeman CA, Heeringa P, et al. Protective role of endothelial nitric oxide synthase. Journal of Pathology 199: 8-17, 2003.
7. Polat F, Diler SB, Azazi I, Öden A. T-786C, G894T, and intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene in bladdercancer cases. Asian Pac J Cancer Prev 16: 2199-2202, 2015.
8 . Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456, 2008.
9. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988.
10. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the T-786C, G894T, and intron 4 VNTR (4a/b)polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol Oncol 31: 1132-1140, 2013.
11. Routledge DJ, Bloor AJ. Recent advances in therapy of chronic lymphocytic leukaemia. Br J Haematol 174:351-367, 2016.
12. Rossi D, Gaidano G. The clinical implications of gene mutations in chronic lymphocytic leukaemia. Br J Cancer 114: 849- 854, 2016.
13. Lu J, Wei Q, Bondy ML, et al. Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107: 2245- 2253, 2006.
14. Chien YH, Bau DT, Jan KY. Nitric oxide inhibits DNA-adduct excision in nucleotide excision repair. Free Radic Biol Med 36: 1011-1017, 2004.
15. Jadeski LC, Chakraborty C, Lala PK. Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int J Cancer 106: 496- 504, 2003.
16. Xu W, Liu L, Smith GC, Charles IG. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat Cell Biol 2: 339-345, 2000.
17. Dhar A, Brindley JM, Stark C, et al. Nitric oxide does not mediate but inhibits transformationand tumor phenotype. Mol Cancer Ther 2: 1285-1293, 2003. 90 UHOD Number: 2 Volume: 27 Year: 2017 International Journal of Hematology and Oncology
18. Kong L, Dunn GD, Keefer LK, Korthuis RJ. Nitric oxide reduces s tumor cell adhesion to isolated rat postcapillary venules. Clin Exp Metastasis 14: 335-343, 1996.
19. Choi BM, Pae HO, Jang SI, et al. Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator. J Biochem Mol Biol 35: 116-126, 2002.
20. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350, 1997.
21. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 86: 30-39, 2000.
22. Han JG, Gao LB, Zhang J, et al. Relationship between Polymorphisms of Angiotensin-converting EnzyEndothelial Nitric Oxide Synthase Gene Intron 4 VNTR and Risk for Cervical Cancer. Life Science Journal 9: 100-104, 2012.
23. Song G, Li Y, Jiang G. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review). Oncol Rep 28: 1935-1944, 2012.
24. Gao X, Wang J, Wang W, et al. eNOS Genetic Polymorphisms and Cancer Risk: A Meta-Analysis and a Case-Control Study of Breast Cancer. Medicine (Baltimore) 94(26): e972, 2015.
25. Demacq C, Vasconcellos VB, Izidoro-Toledo TC, et al. Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL). Clin Chim Acta 411: 1335-1340, 2010.
26. Terrazzino S, La Mattina P, Masini L, et al. Common variants of eNOS and XRCC1 genes may predict acute skin toxicity in breast cancer patients receiving radiotherapy after breast conserving surgery. Radiotherapy and Oncology 103: 199-205, 2012.
27. Hefler LA, Ludwig E, Lampe D, et al. Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecologic Oncology 86: 134-137, 2002.
28. Buraczynska M, Ksiazek P, Zaluska W, et al. Endothelial nitric oxide synthase gene intron 4 polymorphism in patients with end-stage renal disease. Nephrol Dial Transplant 19: 2302- 2306, 2004.
29. Sener EF, Emirogullari ON, Serhatlioglu F, Ozkul Y. The role of endothelial nitric oxide synthase gene G894T and intron 4 VNTR polymorphisms in hemodialysis patients with vascular access thrombosis. Anadolu Kardiyol Derg 14: 239-243, 2014.
30. Ramírez-Patiño R, Figuera LE, Puebla-Pérez AM, et al. Intron 4 VNTR (4a/b) polymorphism of the endothelial nitric oxide synthase gene is associated with breast cancer in Mexican women. J Korean Med Sci 28: 1587-1594, 2013.
31. Sivri N, Unlu A, Palabiyik O, et al. Endothelial nitric oxide synthase intron 4a/b polymorphism in coronary artery disease in Thrace region of Turkey. Biotechnol Biotechnol Equip 28: 1115-1120, 2014.
32. Nasr HB, Dimassi S, M’hadhbi R, et al. Functional G894T (rs1799983) polymorphism and intron-4 VNTR variant of nitric oxide synthase (NOS3) gene are susceptibility biomarkers of obesity among Tunisians. Obes Res Clin Pract 10: 465-475, 2016.
33. Celik U, Yildizdas D, Alhan E, et al. Genetic dilemma: eNOS gene intron 4a/b VNTR polymorphism in sepsis and its clinical features in Turkish children. Turk J Pediatr 50: 114-119, 2008.
34. Wang XL, Sim AS, Badenhop RF, et al. A smoking dependant risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 2: 41-45, 1996.
35. Hou L, Osei-Hyiaman D, Yu H, et al. Association of a 27 bp repeat polymorphism in eNOS gene with ischemic stroke in Chinese Population. Neurology 56: 490-496, 2001.
36. Wang Y, Kikuchi K, Suzuki H, et al. Endothelial Nitric Oxide Synthase gene Polymorphism in intron 4 affects the progression of renal failure in Non - diabetic renal diseases. Nephrol Dial Transplant 14: 2898-2902, 1999.
37. Yeh CC, Santella RM, Hsieh LL, et al. An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. Int J Cancer 124: 1565-1571, 2009.
38. Wu X, Wang ZF, Xu Y, et al. Association between three eNOS polymorphisms and cancer risk: a meta-analysis. Asian Pac J Cancer Prev 15: 5317-5324, 2014.
39. Zhang Y, Jia Q, He Q, et al. The Glu298Asp polymorphism in the NOS3 gene and the risk of prostate cancer. Tumour Biol 35: 4735-4739, 2014.
40. Verim L, Toptas B, Ozkan NE, et al. Possible relation between the NOS3 gene GLU298ASP polymorphism and bladder cancer in Turkey. Asian Pac J Cancer Prev 14: 665-668, 2013.
41. Arikan S, Cacina C, Guler E, et al. The effects of NOS3 Glu298Asp variant on colorectal cancer risk and progression in Turkish population. Mol Biol Rep 39: 3245-3249, 2012.
42. Fu H, Zhang Y, Jin L, Ding Z. Endothelial nitric oxide synthase (eNOS) G894T polymorphism is not associated with breast cancer risk: new evidence. Breast Cancer Res Treat 128: 595- 598, 2011.
43. Lee KM, Choi JY, Lee JE, et al. Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement. Breast Cancer Res Treat 106: 433-438, 2007.

APA	PEHLİVAN M, TOMATIR A, NURSAL A, SAHIN H, pehlivan s (2017). Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. , 85 - 90.
Chicago	PEHLİVAN MUSTAFA,TOMATIR Ayse G,NURSAL Ayşe F,SAHIN Handan H.,pehlivan sacide Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. (2017): 85 - 90.
MLA	PEHLİVAN MUSTAFA,TOMATIR Ayse G,NURSAL Ayşe F,SAHIN Handan H.,pehlivan sacide Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. , 2017, ss.85 - 90.
AMA	PEHLİVAN M,TOMATIR A,NURSAL A,SAHIN H,pehlivan s Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. . 2017; 85 - 90.
Vancouver	PEHLİVAN M,TOMATIR A,NURSAL A,SAHIN H,pehlivan s Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. . 2017; 85 - 90.
IEEE	PEHLİVAN M,TOMATIR A,NURSAL A,SAHIN H,pehlivan s "Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari." , ss.85 - 90, 2017.
ISNAD	PEHLİVAN, MUSTAFA vd. "Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari". (2017), 85-90.

APA	PEHLİVAN M, TOMATIR A, NURSAL A, SAHIN H, pehlivan s (2017). Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. Uluslararası Hematoloji-Onkoloji Dergisi, 27(2), 85 - 90.
Chicago	PEHLİVAN MUSTAFA,TOMATIR Ayse G,NURSAL Ayşe F,SAHIN Handan H.,pehlivan sacide Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. Uluslararası Hematoloji-Onkoloji Dergisi 27, no.2 (2017): 85 - 90.
MLA	PEHLİVAN MUSTAFA,TOMATIR Ayse G,NURSAL Ayşe F,SAHIN Handan H.,pehlivan sacide Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. Uluslararası Hematoloji-Onkoloji Dergisi, vol.27, no.2, 2017, ss.85 - 90.
AMA	PEHLİVAN M,TOMATIR A,NURSAL A,SAHIN H,pehlivan s Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. Uluslararası Hematoloji-Onkoloji Dergisi. 2017; 27(2): 85 - 90.
Vancouver	PEHLİVAN M,TOMATIR A,NURSAL A,SAHIN H,pehlivan s Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari. Uluslararası Hematoloji-Onkoloji Dergisi. 2017; 27(2): 85 - 90.
IEEE	PEHLİVAN M,TOMATIR A,NURSAL A,SAHIN H,pehlivan s "Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari." Uluslararası Hematoloji-Onkoloji Dergisi, 27, ss.85 - 90, 2017.
ISNAD	PEHLİVAN, MUSTAFA vd. "Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari". Uluslararası Hematoloji-Onkoloji Dergisi 27/2 (2017), 85-90.